Aug 16, 2023 6:00 am EDT Eyenovia Acquires U.S. Commercial Rights to APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) from Formosa Pharmaceuticals
Aug 10, 2023 4:05 pm EDT Eyenovia Reports Second Quarter 2023 Financial Results and Provides Business Update
Aug 9, 2023 8:00 am EDT Eyenovia to Present at Upcoming H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
May 11, 2023 4:05 pm EDT Eyenovia Reports First Quarter 2023 Financial Results and Provides Business Update
May 8, 2023 8:00 am EDT Eyenovia Announces FDA Approval of Mydcombi™, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company’s Proprietary Optejet® Device Platform